Figure 1From: Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvementCumulative number of patients improving from baseline in juvenile idiopathic arthritis core outcome variables (dotted lines show non-improvers); ACR, American College of Rheumatology.Back to article page